Oral bioavailability of a low molecular weight heparin using a polymeric delivery system

被引:109
作者
Hoffart, Valerie [1 ]
Lamprecht, Alf [1 ]
Maincent, Philippe [1 ]
Lecompte, Thomas [1 ]
Vigneron, Claude [1 ]
Ubrich, Nathalie [1 ]
机构
[1] INSERM, U734, EA 3452, Pharmaceut Technol Lab, F-54001 Nancy, France
关键词
low molecular weight heparin; oral absorption; nanoparticles;
D O I
10.1016/j.jconrel.2006.03.020
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Low molecular weight heparins (LMWHs) are the standards of anticoagulant for the prevention of deep vein thrombosis (DVT) in patients undergoing arthroplasty and abdominal surgery. However, LMWHs are so far only administered by parenteral route. Thus, they are usually replaced by oral warfarin for outpatient therapy. Since warfarin has a slow onset and high incidence of drug-drug interaction, there is a great need for the development of an oral LMWH formulation. LMWH (tinzaparin)-loaded nanoparticles prepared with a blend of a polyester and a polycationic polymethacrylate by the double emulsion method were administered orally in fasted rabbits. The plasma tinzaparin concentration was measured by a chromogenic anti-factor Xa assay. After oral administration of two doses of tinzaparin-loaded nanoparticles (200 and 600 anti-Xa U/kg), the oral absorption was observed between 4 and 10 or 12 h, with a delayed onset of action ranging from 3 to 4 h. Mean absolute bioavailabilities were 51% and 59% for the two tested doses. We now report that the encapsulation of tinzaparin into nanoparticles is likely to contribute to its oral efficacy with an anticoagulant effect prolonged up to 8 h. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:38 / 42
页数:5
相关论文
共 50 条
[31]   Thromboprophylaxis with low-molecular-weight heparin after cesarean delivery A decision analysis [J].
Blondon, Marc ;
Perrier, Arnaud ;
Nendaz, Mathieu ;
Righini, Marc ;
Boehlen, Francoise ;
Boulvain, Michel ;
De Moerloose, Philippe .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (01) :129-137
[32]   Operative spinal trauma: Thromboprophylaxis with low molecular weight heparin or a direct oral anticoagulant [J].
Hamidi, Mohammad ;
Zeeshan, Muhammad ;
Kulvatunyou, Narong ;
Mitra, Hari S. ;
Hanna, Kamil ;
Tang, Andrew ;
Northcutt, Ashley ;
O'Keeffe, Terence ;
Joseph, Bellal .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (06) :925-933
[33]   Mucoadhesive nanoparticles-based oral drug delivery systems enhance ameliorative effects of low molecular weight heparin on experimental colitis [J].
Yan, Yan ;
Sun, Ying ;
Wang, Pengchong ;
Zhang, Rui ;
Huo, Chuanchuan ;
Gao, Tingting ;
Song, Chenghua ;
Xing, Jianfeng ;
Dong, Yalin .
CARBOHYDRATE POLYMERS, 2020, 246
[34]   Low-molecular-weight heparin for thromboprophylaxis [J].
Camporese, Giuseppe ;
Bernardi, Enrico .
CURRENT OPINION IN PULMONARY MEDICINE, 2009, 15 (05) :443-454
[35]   A study of low molecular weight heparin prescription [J].
Callaert, S ;
Chouaid, C ;
Causse, R ;
Thebault, A .
THERAPIE, 1998, 53 (06) :587-590
[36]   Antiproliferative effects of low molecular weight heparin [J].
Fletcher, JP ;
Ao, PY ;
Hawthorne, WJ .
ANZ JOURNAL OF SURGERY, 2004, 74 (09) :793-796
[37]   Low molecular weight heparin and neuraxial anesthesia [J].
Horlocker, TT .
THROMBOSIS RESEARCH, 2001, 101 (01) :V141-V154
[38]   Low-molecular-weight heparin in oncology [J].
Zacharski, LR ;
Loynes, JT .
ANTICANCER RESEARCH, 2003, 23 (3C) :2789-2793
[39]   Preclinical studies on a low molecular weight heparin [J].
Fareed, J ;
Jeske, W ;
Eschenfelder, V ;
Iqbal, O ;
Hoppensteadt, D ;
Ahsan, A .
THROMBOSIS RESEARCH, 1996, 81 (02) :S1-S25
[40]   Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin [J].
Harenberg, J ;
Huhle, G ;
Piazolo, L ;
Giese, C ;
Heene, DL .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (02) :167-172